“We gave the first dose (…) in children to assess the safety to prevent Kovid-19 in children from 6 months to 11 years, how it is tolerated, and the vaccine (…) Immunity capability “The American company confirmed in a statement to AFP.
Immunogenicity is the ability to trigger an immune response.
According to the clinical trial details published online, three different strengths will be examined first.
“We hope the vaccine can be made available to these young children in early 2022,” Pfizer added. “We pride ourselves on being able to undertake this much-needed study for the option eagerly awaiting children and families for vaccination”.
The Pfizer / BioNTech vaccine is currently offered to people over the age of 16, in countries where it is authorized.
The company said it was being studied in more than 2,200 children between the ages of 12 and 15, the result of which Pfizer hopes the company will “share” soon.
Last week, American biotechnology company Modern also announced that it had begun testing its own vaccine against Kovid-19 on thousands of children between the ages of 6 months to 11 years.
Children are less aware of severe cases of the disease, while it is rare for the youngest of them (less than 10 years). Therefore, their vaccination is not a priority at the moment.
But a small portion may still become seriously ill, or develop what researchers have called a multisystem childhood inflammatory syndrome. Several hundred have been killed since Kovid-19.
In addition, children represent a significant portion of the population, who will likely need to be vaccinated to achieve collective immunity, experts say. For example, people under the age of 18 make up about one-fifth of the American population.